Ronald Martell

Mr. Martell is a serial biopharmaceutical entrepreneur and a founder of multiple biopharmaceutical companies, and has served on the boards of several others. He was most recently Founder and Executive Chairman of Indapta and Chief Executive Officer at Achieve Life Sciences, where he led the merger of the company with Oncogenex. Prior to that, he held similar roles at Sevion, NeurogesX and Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he was instrumental in the deals with Bristol-Myers Squibb and Merck KGaA and built ImClone Systems' worldwide commercial operations and field sales force to market and commercialize Erbitux®. Before joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company's oncology franchise, including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin's lymphoma. Mr. Martell began his career at Roche Pharmaceuticals.